ArticleNature communications2026
Increased WNT10B/FOXO6 signaling promotes cell fate transition in renal tubular cells to aggravate renal inflammation and fibrosis.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Retracted
Authors and funding
15 authors.
Funding
Abstract
Abnormal cell fate transition determines cell instability, which can contribute to disease development. In chronic kidney disease, many renal tubular cells exhibit senescent phenotypes. The fundamental mechanisms of this fate transition remain undetermined. Here we discover that WNT10B, a ligand of the Wnt family, accelerates CKD progression through tubular senescence and proinflammatory microenvironments. Mechanistically, WNT10B mediates metabolic reprogramming from fatty acid oxidation to glycolysis, thus promoting cell senescence and cytokine secretion. Genetic ablation of Wnt10b in male CKD mouse model effectively inhibits cell senescence, inflammation, and fibrogenesis by maintaining metabolic homeostasis. Conversely, Wnt10b transgene in tubular cells aggravates metabolic imbalance, and promotes tubular senescence and fibrogenesis. Forkhead box O6 (FOXO6), a DNA-binding transcription factor, mediates the signal transduction cascade of WNT10B. ChIP-, bulk RNA-, and single-nucleus RNA- sequencing and biological assays verify that FOXO6 transcriptionally modulates PPARA and PKM to control metabolic reprogramming and regulate senescence fate transition in tubular cells. Therefore, the study reveals that WNT10B/FOXO6 signaling controls tubular cell senescence fate, and sheds a light on potential intervention targets to protect against CKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.